Driehaus Capital Management LLC Boosts Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Driehaus Capital Management LLC increased its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 5.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 829,465 shares of the biopharmaceutical company's stock after purchasing an additional 45,521 shares during the quarter. Driehaus Capital Management LLC owned approximately 0.90% of Ultragenyx Pharmaceutical worth $34,896,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Wilmington Savings Fund Society FSB bought a new stake in shares of Ultragenyx Pharmaceutical during the 3rd quarter valued at $83,000. Nordea Investment Management AB grew its position in Ultragenyx Pharmaceutical by 8.9% in the fourth quarter. Nordea Investment Management AB now owns 39,673 shares of the biopharmaceutical company's stock valued at $1,658,000 after acquiring an additional 3,246 shares during the last quarter. Wealth Enhancement Advisory Services LLC increased its position in shares of Ultragenyx Pharmaceutical by 1.4% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 22,047 shares of the biopharmaceutical company's stock worth $928,000 after buying an additional 294 shares during the period. KBC Group NV boosted its stake in Ultragenyx Pharmaceutical by 2,275.8% during the fourth quarter. KBC Group NV now owns 61,010 shares of the biopharmaceutical company's stock worth $2,567,000 after acquiring an additional 58,442 shares in the last quarter. Finally, R Squared Ltd bought a new stake in shares of Ultragenyx Pharmaceutical during the fourth quarter worth about $103,000. Hedge funds and other institutional investors own 97.67% of the company's stock.

Ultragenyx Pharmaceutical Trading Down 2.4%

RARE stock traded down $0.85 during midday trading on Wednesday, hitting $34.55. The company's stock had a trading volume of 225,157 shares, compared to its average volume of 826,922. The company has a market cap of $3.27 billion, a PE ratio of -5.45 and a beta of 0.34. Ultragenyx Pharmaceutical Inc. has a 12 month low of $29.59 and a 12 month high of $60.37. The firm's 50-day moving average is $36.67 and its 200-day moving average is $42.11.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($1.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.54) by ($0.03). The firm had revenue of $139.29 million during the quarter, compared to the consensus estimate of $145.98 million. Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%. The firm's revenue for the quarter was up 28.0% compared to the same quarter last year. During the same period last year, the company earned ($2.03) EPS. Analysts expect that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current year.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CAO Theodore Alan Huizenga sold 967 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $42.10, for a total transaction of $40,710.70. Following the completion of the transaction, the chief accounting officer now directly owns 50,265 shares of the company's stock, valued at approximately $2,116,156.50. This trade represents a 1.89% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Howard Horn sold 1,785 shares of the business's stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of $40.40, for a total value of $72,114.00. Following the completion of the sale, the chief financial officer now directly owns 106,169 shares of the company's stock, valued at approximately $4,289,227.60. The trade was a 1.65% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 125,405 shares of company stock valued at $5,285,169. Insiders own 5.50% of the company's stock.

Analyst Upgrades and Downgrades

RARE has been the subject of a number of analyst reports. Morgan Stanley raised their price objective on shares of Ultragenyx Pharmaceutical from $64.00 to $65.00 and gave the company an "overweight" rating in a research report on Friday, May 9th. Cantor Fitzgerald restated an "overweight" rating and issued a $118.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, February 26th. Canaccord Genuity Group increased their price target on Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the company a "buy" rating in a research note on Tuesday, February 18th. HC Wainwright restated a "buy" rating and issued a $95.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Friday, February 14th. Finally, JPMorgan Chase & Co. raised their target price on shares of Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the stock an "overweight" rating in a research report on Thursday, March 27th. One analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $90.93.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.